Your browser doesn't support javascript.
loading
Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-naïve and biologic-experienced patients with ulcerative colitis in France.
Oppe, Mark; Muresan, Bogdan; Chan, Katie; Radu, Xenia; Schultz, Bob G; Turpin, Robin S; Nucit, Arnaud; Fenu, Elisabetta.
Afiliação
  • Oppe M; Axentiva Solutions, Barcelona, Spain.
  • Muresan B; IQVIA, Health Economics and Outcomes Research, Amsterdam, Netherlands.
  • Chan K; IQVIA, EMEA HE Real-World Methods & Evidence Generation, London, UK.
  • Radu X; IQVIA, EMEA HE Real-World Methods & Evidence Generation, London, UK.
  • Schultz BG; Takeda Pharmaceuticals U.S.A., Inc, US Medical Affairs, Value & Evidence Generation, Lexington, MA, USA.
  • Turpin RS; Takeda Pharmaceuticals U.S.A., Inc, US Value Evidence, Bannockburn, IL, USA.
  • Nucit A; Takeda France S.A.S, Health Economics - Patient Value & Access, Paris, France.
  • Fenu E; Takeda Pharmaceuticals International AG, Global Health Economics, Zurich, Switzerland.
Expert Rev Pharmacoecon Outcomes Res ; 23(2): 205-213, 2023 Feb.
Article em En | MEDLINE | ID: mdl-36541707
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Colite Ulcerativa / Medicamentos Biossimilares Tipo de estudo: Health_economic_evaluation / Prognostic_studies Limite: Humans País como assunto: Europa Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Colite Ulcerativa / Medicamentos Biossimilares Tipo de estudo: Health_economic_evaluation / Prognostic_studies Limite: Humans País como assunto: Europa Idioma: En Ano de publicação: 2023 Tipo de documento: Article